Migraine Prevention Drugs Demonstrate Net Health Benefit
Source: Institute for Clinical and Economic Review
The Institute for Clinical and Economic Review released a final evidence report on three calcitonin gene-related peptide (CGRP) inhibitors for prevention of migraine. Panel members voted that evidence was adequate to demonstrate a net health benefit of the CGRP inhibitors for individuals with chronic migraine and no other available treatment options.
Read Final Evidence Report and Report-at-a-Glance